Advancing Alzheimer's Prevention
Tommorrow Study Collective exists because the science of Alzheimer's prevention is real, it is advancing, and it deserves a dedicated platform that brings it to the people who need it most.
Our Approach
Science-Forward
“Prevention science is only powerful if people can understand and use it.”
Everything we publish is grounded in peer-reviewed research, clinical trial data, and the work of leading institutions. We cover the genetics of early cognitive impairment, investigational therapies, and the evolving landscape of Alzheimer's prevention — translating it into content that is both rigorous and readable.
Accessible
& Empowering
“An informed public is one of the most powerful assets in the fight against Alzheimer's.”
Alzheimer's prevention science should not be locked behind academic paywalls or buried in clinical jargon. We write for families navigating early signs of cognitive change, for caregivers seeking clarity, and for anyone who wants to understand their risk — meeting people where they are without sacrificing scientific accuracy.
Rigorous & Trustworthy
“Trust is built through transparency, accuracy, and a commitment to the evidence.”
Tommorrow Study Collective maintains strict editorial standards across all content. We cite primary sources, acknowledge uncertainty where it exists, and never overstate what the science supports. Our audience deserves honesty — especially when the subject is their own cognitive health.
Our Mission
Tommorrow Study Collective exists to extend the legacy of the TOMMORROW study — one of the first organized efforts to prevent Alzheimer's disease before it begins. We translate complex prevention science into accessible, meaningful content for individuals, families, caregivers, and clinicians who need it most.
Get Involved
The TOMMORROW Study
5yrs
Duration of the TOMMORROW clinical trial, following thousands of cognitively healthy older adults.
1st
Among the first clinical trials globally to target Alzheimer's prevention in cognitively healthy adults using genetic risk biomarkers.
2
Major research institutions — including Emory University’s Alzheimer’s Disease Research Center — recognized the TOMMORROW study’s landmark contribution to prevention science.
* Sources: Alzheimer's Association, Emory ADRC, TOMMORROW clinical trial registry.
In the Press
"The TOMMORROW study represented one of the first serious, organized efforts to intervene in Alzheimer's disease before it begins; a landmark in the history of prevention science."
“Verywell has significantly transformed the healthcare industry by seamlessly connecting patients and healthcare providers, cultivating a supportive space that values health, convenience, and individualized care above all else.”
“Verywell is genuinely reshaping healthcare by uniting patients and medical experts in a powerful way, while creating a culture centered on wellness, ease of access, and personalized healthcare experiences.”
“Verywell is innovatively altering the face of healthcare by effectively linking patients with medical specialists, and promoting a setting that emphasizes overall health, user-friendly experiences, and tailored patient solutions.”
Latest Research & News
Join Our SMS List
Sign up for SMS messages to receive immediate notifications on new trial openings, research breakthroughs, any other Alzheimers news.
Thank you for subscribing!
Please try entering your phone number again.
The content published by Tommorrow Study Collective Inc. is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your physician or a qualified healthcare provider regarding any questions about your health or participation in clinical research. In the event of a medical emergency, call emergency services immediately.
